Literature DB >> 3037810

6-Methylpurine, 6-methyl-9-beta-D-ribofuranosylpurine, and 6-hydroxymethyl-9-beta-D-ribofuranosylpurine as antiviral metabolites of Collybia maculata (Basidiomycetes).

K Leonhardt, T Anke, E Hillen-Maske, W Steglich.   

Abstract

6-Methylpurine, 6-methyl-9-beta-D-ribofuranosylpurine and 6-hydroxymethyl-9-beta-D-ribofuranosylpurine were isolated from mycelial cultures of Collybia maculata and their antifungal, cytotoxic and antiviral activities investigated. This is the first report on the natural occurrence of these compounds.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037810     DOI: 10.1515/znc-1987-0415

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  3 in total

1.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

2.  The pharmacological potential of mushrooms.

Authors:  Ulrike Lindequist; Timo H J Niedermeyer; Wolf-Dieter Jülich
Journal:  Evid Based Complement Alternat Med       Date:  2005-09       Impact factor: 2.629

3.  Improved synthesis of beta-D-6-methylpurine riboside and antitumor effects of the beta-D- and alpha-D-anomers.

Authors:  Canio J Marasco; Paula J Pera; Arthur J Spiess; Ralph Bernacki; Janice R Sufrin
Journal:  Molecules       Date:  2005-08-31       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.